SCHEMBL6041560

SCHEMBL6041560

CC(C)(C)OC(=O)N1CCC(O)(c2ccc(=O)[nH]c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.51
KDM4E B2RXH2 2/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
ATM Q13315 1/20 0.41
DRD2 P14416 3/20 0.41
CTSD P07339 1/20 0.39
CTSE P14091 1/20 0.39
BACE1 P56817 1/20 0.39
CCR5 P51681 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TACR1 P25103 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
HCAR1 Q9BXC0 1/20 0.39
CRBN Q96SW2 1/20 0.39
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18432250 0.80 ESR2 (0.48) GPR119MAPTTSHRALOX15ATM
SCHEMBL11956931 0.80 GPR119 (0.53) GPR119TSHRALOX15ATMDRD2
SCHEMBL6041455 0.80 KMT2A (0.38) DRD2OPRK1
SCHEMBL557597 0.79 DRD2 (0.61) KDM4EMAPTDRD2SMN1; SMN2
SCHEMBL12561460 0.79 DRD2 (0.46) GPR119MAPTTSHRALOX15ATM
SCHEMBL15379660 0.79 NR1H2 (0.49) GPR119MAPTTSHRALOX15ATM
SCHEMBL1199600 0.79 RORC (0.51) GPR119TSHRALOX15ATMDRD2
SCHEMBL3266179 0.79 RORC (0.51) DRD2
SCHEMBL240381 0.79 TSHR (0.57) GPR119KDM4ETSHRALOX15ATM
SCHEMBL6802425 0.78 ALDH1A1 (0.55) GPR119MAPTTSHRDRD2CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 GPR119 856/4885KDM4E 2501/4885MAPT 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.